In a randomized controlled study of 55 hypertensive patients, xuezhikang therapy resulted in significant reductions in serum and urine b2-microglobulin (b2-M), and serum immune complex (IC) compared with baseline, as well as with placebo. Urine a1-microglobulin (a1-M) and b2-M were positively correlated with serum IC and IgG by linear regression analysis, and only with serum IC on multivariate regression analysis. The data suggested that the significant modification of xuezhikang on urinary microglobulin excretion was probably associated with its immunomodulating effect.
Alpha1-microglobulin is a low-molecular-weight glycoprotein produced by the liver cells and released into all the main body fluids.
1,2 b2-M, a light-chain protein of the class I major histocompatibility complex (MHC-I), is an important component of the cell surface. 3, 4 It is also of note that the increased a1-M and b2-M levels in urine are a sign of early renal dysfunction in hypertensive patients, but the possibly increased synthesis by karyocytes (such as lymphocytes) is often neglected.
Xuezhikang is an extract from Monascus purpureus (specially made red yeast rice or Hongqu) and is rich in lovastatin, and other active ingredients. 5 Xuezhikang has been found to have a marked modulating effect on lipids and other pleiotropic effects, including inhibition of inflammation, improvement of vascular endothelial function and antioxidant load. 6, 7 This study was designed to investigate whether 72 weeks of treatment with xuezhikang reduced a1-M and b2-M levels in serum and urine, and whether the changes were related to improvement of abnormal immunity in patients with hypertension.
It was a randomized, single blind and placebocontrolled study, involving 55 consecutive patients who were diagnosed with essential hypertension in the outpatient clinic of the Chinese PLA General Hospital (Beijing, China) between February and December 2004. These patients had not received any or irregular anti-hypertensive medication, and their blood pressure was 4140/90 mm Hg but o180/110 mm Hg, accompanied by normal blood low-density lipoprotein cholesterol level (p3.37 mmol/l according to NCEP ATP III criteria for patients with moderate risk of coronary heart disease) 8 without statins. The Ethics Committee of the Chinese PLA General Hospital approved the study protocol, and all the participants gave written informed consent.
The patients who were eligible for the trial were subjected to treatment with 20 mg extended-release nifedipine (Qingdao Huanghai Pharmaceutical Co. Ltd, Qingdao, China) twice daily for 72 weeks to achieve blood pressure o140/90 mm Hg. Then, all of them were randomized into two groups according to successive number: odd numbers for the xuezhikang group (n ¼ 28, xuezhikang 1200 mg/d; WBL Peking University Biotech Co., Ltd, Beijing, China) and even numbers for the placebo group (n ¼ 27, a matching placebo). During the study, patients were not allowed to receive any other antihypertensive drugs or other lipid-lowering agents. There was no significant difference in baseline characteristics between the two groups. Thirty age-and gendermatched normotensive patients were selected as a control group for the comparison of relevant parameters.
Serum levels of immune parameters and total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein-cholesterol were analysed at baseline and after 24 and 72 weeks of treatment. Serum and urine levels of a1-M and b2-M were measured by a radioimmunoassay, and serum levels of immunoglobulins and IC were determined by speed scattering turbidimetry.
Data were analysed with the use of SPSS (version 13.0) and were presented as mean±s.d. Differences between intra-and inter-group means were analysed by paired Student's t-test or one-way analysis of variance (ANOVA). Correlations were calculated by Spearman's correlation analysis and multivariate regression analysis.
After 72 weeks of treatment, the serum levels of fasting total cholesterol and low-density lipoprotein cholesterol were significantly reduced by 14.7 and 27.3% (Po0.01), respectively. Serum and urine levels of a1-M and b2-M were significantly higher in the hypertensive patients than those in normotensive controls. Xuezhikang therapy caused significant reduction in serum and urine b2-M levels at weeks 24 and 72, but in urine a1-M levels only at week 24 compared with baseline and placebo group (Figure 1) .
Serum IgG and IC levels in hypertensive patients were significantly higher than those in normotensive patients (Po0.01). After 72 weeks of treatment with xuezhikang, compared with baseline, only serum IC level was decreased significantly (À21.2%, Po0.01) and when compared with the placebo group serum IgG and IC levels were also decreased significantly (À12.4%, Po0.05 and À29.9%, Po0.01 respectively).
The linear regression models showed that baseline urine a1-M was positively correlated to serum IC (r ¼ 0.728, Po0.001) and IgG (r ¼ 0.694, Po0.001); and urine b2-M was positively correlated to serum b2-M (r ¼ 0.660, Po0.001), IC (r ¼ 0.760, Po0.001) and IgG (r ¼ 0.708, Po0.001). The reduction in urine a1-M (R 2 ¼ 0.483, P ¼ 0.001) and b2-M levels (R 2 ¼ 0.496, P ¼ 0.001) was positively correlated to serum IC by multivariate regression analysis.
It has been reported that patients with essential hypertension may show an abnormal immune response. 9 This study indicated that serum levels of immune factors, such as IC and IgG were significantly higher in patients with essential hypertension than in normotensive patients. Circulating IC and IgG cause endothelial dysfunction by complement activation, which results in low-grade chronic inflammation of the vascular wall, and may enhance the atherosclerotic process. 10, 11 Thus, the increase in serum IC and IgG levels indicates the presence of an abnormal immune response, possibly as an influencing factor for the development of atherosclerosis in hypertensive patients.
With xuezhikang administration, urine b2-M levels were decreased significantly, whereas the decrease in urine a1-M was not consistent in our hypertensive patients. Hypertension and hyperlipidemia are important risk factors for proteinuria. However, the blood pressure levels were well matched at baseline, and only extended-release nifedipine was administrated with similar blood pressure at week 72 between the two groups. Moreover, our study was conducted in patients with normal low-density lipoprotein cholesterol levels, and no significant correlation of the change was found between lipid profile and microglobulin with xuezhikang therapy. Thus, it is indicated that the beneficial effect of xuezhikang on urinary microglobulin excretion is independent of changes in blood pressure and lipid level in these patients.
This study demonstrated that the urinary excretion of a1-M and b2-M was positively correlated with serum levels of immune factors; in particular, the IC level was an independent factor that determined changes in urine a1-M and b2-M levels with xuezhikang therapy, upon multivariate analysis. It is likely that the inhibition of abnormal immune response by xuezhikang also involved a mechanism related to urine a1-M and b2-M in hypertensive patients, although no similar study has as yet been reported.
Statins have recently been found to act as direct inhibitors of induction of MHC-I and MHC-II expression by interferon-g, and thus as repressors of MHC-II-mediated T-cell activation in several cell types. 12 As there is a large amount of lovastatin contained in xuezhikang, 7 it seems reasonable to speculate that xuezhikang exerts a similar influence as the statins on MHC-I and MHC-II expression. Furthermore, xuezhikang contains several other active ingredients, 7 which are speculated to have a synergistic function in immunomodulation. As b2-M is a light-chain protein of MHC-I, the decreased level of serum b2-M is presumed to be related to the inhibition of MHC-I expression after xuezhikang therapy.
In summary, long-term administration of xuezhikang resulted in a reduction of urinary microglobulin excretion associated with reduced serum levels of b2-M, IgG and ICs, independent of blood pressure and lipid changes. The finding may be of importance for further exploring new strategies in cardiovascular protection for hypertensive patients.
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